Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CureVac, an mRNA vaccine company, announced the results of Phase I/IIa trial which assessed CV9201, an mRNA-based cancer vaccine, in patients with NSCLC stage IIIB/IV after first-line chemo-radiotherapy or chemotherapy, respectively.
Subscribe to our email newsletter
The trial was intended to test the safety and toxicity of CV9201, besides its ability to induce antigen-specific humoral and cellular immune responses in cancer patients.
The trial with CV9201, tested an immunotherapy based on CureVac´s RNActive vaccination technology in patients after heavy pre-treatment with chemotherapy and 65% of the phase IIa study patients responded to at least one antigen out of the five antigens in CV9201.
The study evaluated a five dose regime of CV9201 delivered via intradermal injection in 46 patients and found that CV9201 is safe, well tolerated and biologically active.